Atypical HUS: Time to take stock of current guidelines and outcome measures?

Pediatric Nephrology

Volumn 28, Issue 5, 2013, Pages 675-677

  Rees, Lesley ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Acute kidney injury; Hemolytic uremic syndrome; Thrombocytopenia

Indexed keywords

COMPLEMENT FACTOR H; ECULIZUMAB; FRESH FROZEN PLASMA; MEMBRANE COFACTOR PROTEIN;

GENE MUTATION; GENETIC IDENTIFICATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; UNSPECIFIED SIDE EFFECT; VASCULAR ACCESS;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL PROTOCOLS; COMPLEMENT ACTIVATION; GENETIC PREDISPOSITION TO DISEASE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MUTATION; PHENOTYPE; PLASMAPHERESIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84880573581     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2423-x     Document Type: Review

References (8)

1. Taylor CM, Machin S, Wigmore SJ, Goodship THJ, on behalf of a working party from the Renal Association, the British Committee for Standards in Haematology and the British Transplant Society (2009) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 148:37-47
2. Bu F, Borsa N, Gianluigi A, Smith RJH (2013) Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Devel Immunol. doi: 10.1155/2012/370426
3. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor MC, Van de Kar N, VandeWalle J, Zimmerhackl LB, The European Paediatric Study Group for HUS (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687-696
4. Loirat C, Frémeaux-Bacchi Orphanet V (2011) Atypical hemolytic uremic syndrome. J Rare Dis 6:60
5. Clark WF (2012) Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange. Semin Dial 25:214-219
6. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V, on behalf of the French study group fo aHUS/C3G (2013) Use of eculizumab for atypical HUS and C3 glomerulopathies. Nat Rev Nephrol 8:643-657
7. Gulleroglu K, Fidan K, Hançer VS3, Umut Bayrakci U, Baskin E, Soylemezoglu O (2013) Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab. Pediatr Nephrol. doi: 10.1007/s00467-013-2416-9
8. Barbour T, Johnson S, Cohney S, Hughes P (2102) Thrombotic microangiopathy and accosiated renal disorders. Nephrol Dial Transplant 27:2673-2685